Viracta Therapeutics Inc
NASDAQ:VIRX
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
V
|
Viracta Therapeutics Inc
NASDAQ:VIRX
|
US |
|
H
|
Hydrogene De France SA
F:9QW
|
FR |
Viracta Therapeutics Inc
Viracta Therapeutics, Inc. a clinical-stage, biomarker-directed precision oncology company focused on new medicines for the treatment of virus-associated malignancies. The company is headquartered in Cardiff-By-The-Sea, California and currently employs 24 full-time employees. The company went IPO on 2005-09-27. The firm is focused on the development of new medicines targeting virus-associated malignancies. The firm conducts clinical trials for its combination product candidate as a therapy for the treatment of relapsed/refractory Epstein-Barr virus-positive lymphoma. The firm is conducting three clinical trials for its lead product candidate, Nana-val, in EBV+ lymphomas and solid tumors, including a Phase II registrational trial of Nana-val in EBV+ lymphomas. Its lead product candidate is an all-oral combination of nanatinostat. Its development pipeline also includes vecabrutinib, a clinical-stage non-covalent ITK/BTK inhibitor and VRx-510, a preclinical-stage PDK-1 inhibitor. Its novel synthetic lethality approach targets the EBV genome to enable the killing of the tumor cells by inducing the expression of certain viral kinase genes which in-turn activate an antiviral drug.
Viracta Therapeutics, Inc. a clinical-stage, biomarker-directed precision oncology company focused on new medicines for the treatment of virus-associated malignancies. The company is headquartered in Cardiff-By-The-Sea, California and currently employs 24 full-time employees. The company went IPO on 2005-09-27. The firm is focused on the development of new medicines targeting virus-associated malignancies. The firm conducts clinical trials for its combination product candidate as a therapy for the treatment of relapsed/refractory Epstein-Barr virus-positive lymphoma. The firm is conducting three clinical trials for its lead product candidate, Nana-val, in EBV+ lymphomas and solid tumors, including a Phase II registrational trial of Nana-val in EBV+ lymphomas. Its lead product candidate is an all-oral combination of nanatinostat. Its development pipeline also includes vecabrutinib, a clinical-stage non-covalent ITK/BTK inhibitor and VRx-510, a preclinical-stage PDK-1 inhibitor. Its novel synthetic lethality approach targets the EBV genome to enable the killing of the tumor cells by inducing the expression of certain viral kinase genes which in-turn activate an antiviral drug.
